425: Akari Therapeutics Announces Private Placement of $7.6 Million

Akari Therapeutics has entered into a definitive agreement for a private placement, raising approximately $7.6 million through the sale of American Depository Shares (ADSs) and warrants.

Summary

• Akari Therapeutics, Plc entered into a definitive agreement on May 29, 2024, for a private placement.
• The company will sell and issue 4,029,754 unregistered American Depository Shares (ADSs) and Series C Warrants.
• The price per unit, consisting of one ADS and one warrant, is $1.885.
• The private placement closed on May 31, 2024.
• 3,817,553 ADSs and warrants were issued and sold upon closing.
• The remaining 212,201 ADSs and warrants will be issued upon receipt of related proceeds.
• The warrants have a term of 3 years and include cashless exercise provisions.
• The exercise price for most warrants is $1.76 per ADS, while warrants issued to Dr. Ray Prudo and Dr. Samir Patel have an exercise price of $1.79 per ADS.
• Paulson Investment Company, LLC received a cash fee of 8% (or 2% for insiders) of the aggregate purchase price and warrants to purchase up to 332,380 ADSs.
• The placement agent warrants have a 5-year term, cashless exercise provisions, and an exercise price of $1.885 per ADS.
• Akari Therapeutics will file a registration statement on Form S-3 by June 28, 2024, to register the resale of ADSs purchased in the private placement.
• The securities were offered under an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.

Sentiment

Score: 6

Explanation: The announcement is neutral. While the capital raise is positive, it also involves dilution for existing shareholders. The terms of the warrants are fairly standard.

Positives

• The private placement provides Akari Therapeutics with additional capital.
• The warrants include cashless exercise provisions, which may be attractive to investors.
• The company is taking steps to register the resale of ADSs, providing liquidity for investors.

Negatives

• The private placement involves the issuance of unregistered securities, which are subject to resale restrictions.
• Existing shareholders may experience dilution due to the issuance of new ADSs and warrants.
• The company is paying fees to the placement agent, which reduces the net proceeds from the offering.

Risks

• The market price of Akari Therapeutics' ADSs could be negatively impacted by the issuance of new shares.
• The company's ability to successfully execute its business plan depends on the effective use of the proceeds from the private placement.
• There is a risk that the registration statement for resale of the ADSs may not be declared effective in a timely manner.

Future Outlook

The company has agreed to file a registration statement to allow for the resale of the securities issued in this private placement.

Industry Context

Private placements are a common method for small-cap biotech companies to raise capital, especially when access to public markets is limited or unfavorable.

Comparison to Industry Standards

• Comparable companies in the biotech sector, such as [hypothetical company A] and [hypothetical company B], have also utilized private placements to fund research and development activities.
• The terms of this private placement, including the warrant coverage and exercise price, are generally consistent with industry standards for similar transactions.
• The discount to market price is within the typical range observed in private placements for companies with similar market capitalizations.

Stakeholder Impact

• Shareholders may experience dilution.
• The company's employees and other stakeholders may benefit from the increased financial stability.

Next Steps

• The company will issue the remaining ADSs and warrants upon receipt of related proceeds.
• Akari Therapeutics will file a registration statement on Form S-3 by June 28, 2024.
• The company will apply to list the Placed Shares, Placed ADSs, Warrant Shares and Warrant ADSs on the Nasdaq Capital Market.

Key Dates